# US 2022/0033387 A1 · 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033387 A1
- Document ID: US20220033387A1
- Status: Published application
- Kind: A1
- Application number: 17/278,625
- Filed: 2019-09-23
- Published: 2022-02-03
- Earliest claimed: 2018-09-25
- Assignees: The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Applicants: The United States of America, AS Represented By the Secretary, Department of Health and Human Servic
- Inventors: Joel Morris; Donn G. Wishka; Omar Diego Lopez
- Web page: https://patentgrep.com/patent/US20220033387A1

## CPC

- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07H 19/12: Triazine radicals
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Halogenated analogs of 5-aza-2′-deoxycytidine, such as halogenated analogs of 5-aza-4′-thio-2′-deoxycytidine (5-aza-T-dCyd) are described. Pharmaceutical compositions including a halogenated analog and methods of using the halogenated analogs to inhibit neoplasia are described. In some examples, the halogenated analogs have a structure according to formula Ia, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:

## Claims

### Claim 1

A compound according to formula Ia, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:
where X is halo;
Y is hydrogen, halo, or deuterium;
each R independently is hydrogen or deuterium; and
Ra is hydrogen, deuterium, alkyl, alkoxy, amino, or halo.

### Claim 2 (depends on 1)

The compound of claim 1, wherein:
(i) X is F; or
(ii) Y is hydrogen or F; or
(iii) each R is hydrogen; or
(iv) Ra is hydrogen; or
(v) any combination of (i), (ii), (iii), and (iv).

### Claim 3 (depends on 1)

The compound of claim 1 having a stereochemistry according to any one of formulas IIa-Va or any combination thereof

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is
or any combination thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is
or any combination thereof.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound is 4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydro-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-1,3,5-triazin-2(1H)-one:

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is formulated for intravenous, oral, intraperitoneal, subcutaneous, rectal, or buccal administration.

### Claim 9 (depends on 1)

A method of inhibiting a neoplasia, comprising:
contacting neoplastic cells with an effective amount of a compound according to claim 1.

### Claim 10 (depends on 9)

The method of claim 9, wherein contacting the neoplastic cells with the effective amount of the compound reduces proliferation of the neoplastic cells.

### Claim 11 (depends on 9)

The method of claim 9, wherein the compound is 4-amino-1-((2R,3S,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl-1,3,5-triazin-2(1H)-one:

### Claim 12 (depends on 9)

The method of claim 9, wherein contacting the neoplastic cells with the effective amount of the compound comprises administering a therapeutically effective amount of the compound to a subject having or suspected of having a disease characterized at least in part by presence of neoplastic cells.

### Claim 13 (depends on 12)

The method of claim 12, wherein the disease is a cancer.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cancer is a cancer of the kidney, bladder, breast, colon, endometrium, skin, blood, pancreas, prostate, bone, liver, lung, esophagus, or central nervous system.

### Claim 15 (depends on 12)

The method of claim 12, wherein administering the therapeutically effective amount of the compound to the subject reduces a sign or symptom of the disease.

### Claim 16 (depends on 15)

The method of claim 15, wherein:
the sign or symptom of the disease is a solid tumor and administering the therapeutically effective amount of the compound to the subject reduces growth of the solid tumor, reduces a volume of the solid tumor, reduces metastasis of the solid tumor, or any combination thereof; or
the sign or symptom of the disease is an abnormal complete blood count and administering the therapeutically effective amount of the compound to the subject at least partially normalizes the complete blood count.

### Claim 17 (depends on 12)

The method of claim 12, wherein administering the therapeutically effective amount of the compound comprises administering a pharmaceutical composition comprising the therapeutically effective amount of the compound to the subject.

### Claim 18 (depends on 12)

The method of claim 12, wherein administering comprises intravenous, oral, intraperitoneal, subcutaneous, rectal, or buccal administration.

### Claim 19 (depends on 12)

The method of claim 12, further comprising administering a second active agent to the subject.

### Claim 20 (depends on 19)

The method of claim 19, wherein the second active agent is an anti-cancer agent, an anti-inflammatory agent, an antimicrobial agent, an antiviral agent, an anesthetic agent, or any combination thereof.
